

The Legal Implications of Personalized Medicine

OBA Professional Development & CBA Biotechnology Committee

Date: Friday, October 26, 2018 | 9:00 AM – 12:00 PM
Location: Twenty Toronto Street Conferences and Events
Agenda: 8:30 am Registration
9:00 am Program Starts
12:00 pm Program Concludes



In-Person



Webcast



Professionalism Hours: This program contains **0h 30m**
Substantive Hours: This program is eligible for up to **2h 30m**

The OBA has been approved as an Accredited Provider of Professionalism Content by The Law Society of Upper Canada.

Our genome is personal, so shouldn't our medicine be as well? As the pace of development in personalized or precision medicine accelerates, many new issues and challenges arise out of the ethical and practical implications around privacy, access, and ownership of personal genomic data. What is the true value of personalized medicine and who pays for it? What technology or information can be protected with patents or other rights? Whether you are in-house counsel or in private practice, this innovative program will tackle these questions and provide insightful answers. Join us for this unique and valuable program.

Program Chairs: **Geoff Mowatt**, DLA Piper (Canada) LLP
Inta Gaikis, Novo Nordisk Canada

9:00 am	Welcome and Opening Remarks
9:05 am	Personalized Medicine - What is it and why are we talking about it? Roger Tam , Vice-President, Legal, Roche Canada <ul style="list-style-type: none">Overview of the landscapeRecent developments in the areaEmerging issuesRegulatory implications and the role of Health Canada
9:35 am	Bioethics - Too Much Information? Ian Stedman , Osgoode Hall Law School, York University <ul style="list-style-type: none">Legal and ethical obligations and concerns to consider:<ul style="list-style-type: none">Right to informed decisions and prevention - where is the line?Risk of discrimination - family, workplace, insuranceTargeted marketingProduct liability implicationsAdvising clients of bioethical issues
10:05 am	Networking Break
10:20 am	Genomic Data: Proprietary, Private, or Open? Teresa Reguly , Torys LLP Adrian Thorogood , Regulatory and Ethics Work Stream Manager, Global Alliance for Genomics and Health <ul style="list-style-type: none">Biobanks, genetic databases, and data sharing to support personalized medicineGenetic databases: ownership, access, and controlGenetic databases: quality management and certificationAn individual right to access genomic data
10:50 am	Evolving Technology and Protecting Innovation Graham McNeil , Head of Legal, Celgene Canada Sara Zborovski , Norton Rose Fulbright LLP <ul style="list-style-type: none">What can be protected/owned?Patent strategies for digital health and gene technologiesOther procurement and enforcement strategiesRegulatory approvals
11:25 am	Reimbursement and the Payer Perspective Wayne Critchley , Global Public Affairs <ul style="list-style-type: none">Assessing the value of technology/treatmentReimbursement pathways and challenges in Canada
11:55 am	Questions and Concluding Remarks
12:00 pm	Program Concludes

PROGRAM REGISTRATION IS ONLINE www.oba.org/pd

Questions? pd@oba.org